Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Anaphore

  • RuiYi Licenses mAb Development to China's Genor
    ... Headquartered in La Jolla, CA, RuiYi-which changed its name in October from Anaphore-carries out drug discovery in China, at the Zhangjiang Hi-Tech Park in Pudong, Shanghai. ...
    5-16-2013
  • RuiYi, CMC Collaborate to Speed mAb Development
    Headquartered in La Jolla, CA, RuiYi-which changed its name in October from Anaphore-carri... Antigen Presenting (iCAP) system. Anaphore acquired the original RuiYi in March ...
    5-14-2013
  • GEN | Biolinks
    AltheRx Pharmaceuticals Altravax Amarin Ambit Biosciences Ambrx Ambry Genetics Amgen Amicus Therapeutics Amnis Amplimmune Amresco Amunix Amylin Pharmaceuticals Anaphore Anaspec ...
  • Shire Rare-Disease Partnerships Expand
    with another commercial partner last October, when it granted RuiYi (formerly Anaphore) a worldwide exclusive license to develop and commercialize ARGX-109, an anti-IL-6 ...
    1-7-2013
  • RuiYi Nabs Rights to arGEN-X IL-6 mAb
    RuiYi (formerly Anaphore) negotiated a worldwide exclusive license to ArGEN-X' preclinical ... and a research base in Shanghai, results from the firm's acquisition by Anaphore in March. ...
    10-4-2012
  • People in the News
    Dr. Bowdish was co-founder, president, and CEO of Anaphore. She also founded the firm Prolifaron and served as president of Alexion Antibody Technologies. InterMune appointed ...
    4-1-2012
  • Tanabe Research Labs and Anaphore Ally to Develop Atrimers for...
    Tanabe Research Laboratories is teaming up with Anaphore for an R&D program that aims to ... to bind potently and specifically to virtually any target of interest, Anaphore claims. ...
    12-13-2010

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll